Looking for a specific type of study? Finding the right fit is simple:
- Select your criteria below
- Press submit to view your results
The following projects are currently open and enrolling volunteers. These studies have been evaluated and approved by the research team at Dr. Susan Love Foundation and members of our external Scientific Advisory Committee, comprised of researchers, clinicians, and advocates.
If you would like to learn about the studies we recruited for in the past, please click here.
Select your criteria:
Researcher: Steven Narod, MD, and Carol Townsley, MD; Women’s College Research Institute, Toronto, ON, Canada.
Broadcast date: March 30, 2021
Doctors do not know which women treated for early-stage estrogen receptor-positive (ER+) breast cancer will have their cancer come back in their breast or spread to other parts of their body. The purpose of this study is to collect information from women who have been diagnosed with ER+ breast cancer in order to learn which factors increase or decrease the risk of having a recurrence.
Researcher: Kelly Metcalfe, PhD, Women’s College Research Institute, Toronto, ON, Canada
Broadcast date: March 18, 2021
Research has shown that people who have inherited a mutation in the PALB2 gene are at increased risk for breast cancer. We have learned a lot about breast cancer that occurs in people with a BRCA mutation. But much less is known about breast cancer in those with a PALB2 mutation. The purpose of this study is to learn more about the effectiveness of screening and the effectiveness of different breast cancer treatment regimens in people with an inherited PALB2 mutation.
Researcher: Diane Von Ah, PhD, RN, FAAN, Indiana University School of Nursing
Broadcast date: February 18, 2021
The purpose of this study is to identify underlying factors (such as age, stress level, and quality of sleep) that may be linked to memory and concentration problems that some people experience after going through treatment for cancer. The goal is for researchers to gain a better understanding of how these factors are related in order to find solutions to reduce the negative effects of treatment.
Researcher: Jennifer Huberty, PhD; Linda Larkey, PhD; Arizona State University
Broadcast date: December 22, 2020
The purpose of this study is to investigate the effects of a mobile health-related app on cancer patients’ symptoms.
Randomized Clinical Trial of RANKL Inhibition with Denosumab on Mammographic Density in High Risk Premenopausal Women with Dense Breasts
Researcher: Adetunji T. Toriola, MD, PhD, MPH, Washington University School of Medicine, St. Louis, MO
Broadcast date: September 11, 2020
Studies have shown that women with dense breasts are at increased risk for breast cancer. The drug tamoxifen has been shown to reduce breast cancer risk in high-risk women in part by reducing breast density. The purpose of this study is to see whether the drug denosumab (Prolia), which is used to treat osteoporosis, can reduce breast density. If the drug reduces breast density, it could provide a new treatment option for risk reduction.
Researcher: Kathryn Greene, PhD, Rutgers University; Katie Devine, PhD, Rutgers Cancer Institute of New Jersey; Smita Banerjee, PhD, Memorial Sloan Kettering Cancer Center; Maria Venetis, PhD, Rutgers University; Danielle Catona, PhD, George Mason University; Maria Checton, PhD, College of Saint Elizabeth.
Broadcast date: June 12, 2020
Studies have shown that effective communication is important for good health outcomes. However, little is known about the types of communication that takes place between cancer patients and their “companions”—the friends or family members who accompany them to many or most of their cancer-related appointments. For this study, researchers will have current cancer patients, former cancer patients, and patient companions complete a survey about how they felt about their communication experiences. The researchers will use the information to develop a program that can help cancer patients and their companions communicate better during cancer-related appointments.
Researcher: Shelli Kesler, PhD, University of Texas at Austin, Austin, TX
Broadcast date: January 8, 2020
Please note, this study was updated on 10/09/2020. We need women with a history of breast cancer who have completed chemotherapy treatment at least 1 month ago and healthy women to help researchers gain a better understanding of the effects of chemotherapy on the brain. The research team is looking for volunteers age 35 to 60. The effects that cancer and its treatments have on brain health are not well understood. To address this problem, researchers at the University of Texas in Austin are examining brain function with computerized tests (done remotely via videoconferencing) and brain activity scans (done in person at the University, following strict COVID-19 guidelines). The purpose of this study is to evaluate brain function associated with breast cancer chemotherapy. Information about brain function from healthy women is needed for comparison with women who have breast cancer.
Researcher: Tim Ahles, PhD, and James Root, PhD, at Memorial Sloan Kettering Cancer Center
Broadcast date: November 5, 2018
Breast cancer treatments may have an impact on how the brain processes information and emotions as well as on a person’s attention span and behavior. To better understand and measure these changes, researchers at Memorial Sloan Kettering Cancer Center developed a new thinking test called the Sensory-Attention-Executive (SAE) Battery. The research team needs women who have not had cancer to participate in a study that will evaluate whether these tests accurately capture how the brain may change over time.
Researcher: Mark Burkard, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Broadcast date: May 10, 2018
Some people live for many years following a metastatic breast cancer diagnosis. To gain insight into why, researchers want to learn more about the medical history and health habits of people living with metastatic breast cancer. If you take part in this study, you will complete an online survey that will ask you questions about diet, exercise, health behaviors and medical care. Some participants who fill out the survey will also be invited to participate in an optional sub-study, which includes a medical record review, a blood or saliva sample, and tumor analysis. Findings from the survey and optional sub-study may help the research team discover how to help people live longer after a diagnosis of metastatic breast cancer.
Researcher: Seema Khan, MD, Northwestern University, Chicago, IL, Joseph Michael Guenther, MD, St. Elizabeth HealthCare, Edgewood, KY, Amy Degnim, MD, Mayo Clinic, Rochester, MN, Melissa Pilewskie, MD, Memorial Sloan Kettering Cancer Center, New York, NY, E. Shelley Hwang, MD, Duke University, Durham, NC, Stephen Grobmyer, MD, Cleveland Clinic, Cleveland, OH
Broadcast date: February 16, 2018
The purpose of this study is to compare the effects of a tamoxifen pill to tamoxifen (4-OHT) gel on breast cells in women with ER+ DCIS. This study will investigate what effects each treatment has on the DCIS and what side effects each treatment may cause. Prior studies show that the topical gel stays mainly in the breast itself with very little getting into the blood. The eventual goal is to provide women with DCIS with an alternative to oral tamoxifen treatment.
Researcher: Laura Esserman, MD, MBA, University of California, San Francisco, CA and her partners from the Athena Breast Health Network (a collaboration across the five University of California Medical Centers and Sanford Health)
Broadcast date: February 16, 2018
Women receive mixed messages about what type of breast cancer screening they should have and how often they should have mammograms. The WISDOM Study compares the routine, annual mammogram schedule to a personalized screening schedule based on a woman’s individual risk factors. The goal of the study is to determine the best way to use mammograms to improve breast cancer screening while reducing the number of call backs, false alarms, and biopsies for women who do not have breast cancer.
Phase I Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Researcher: Alexandra Zimmer, M.D., at the National Cancer Institute, Bethesda, MD
Broadcast date: September 19, 2017
The purpose of this study is to investigate whether using Temodar and Kadcyla together decreases the chance of patients with HER2+ metastatic breast cancer developing new brain metastases. Approximately 18 participants will take part in this study. Participants enrolled in this trial may be eligible to receive compensation for their travel expenses.
Researcher: Steven Narod, MD, Women's College Research Institute, Toronto, Ontario, Canada
Broadcast date: March 15, 2017
Genetic and non-genetic factors are believed to influence whether a woman with a BRCA1, BRCA2, and/or PALB2 mutation goes on to develop breast and/or ovarian cancer. The study is trying to identify which hormonal, reproductive, and lifestyle factors may increase cancer risk in this high-risk group.